Former Gilead CEO lands on board of East Bay gene therapy company seeking $75M IPO November 18, 2020 San Francisco Biotechnology Network News News Comments Off on Former Gilead CEO lands on board of East Bay gene therapy company seeking $75M IPO 4D Molecular Therapeutics' gene therapies are mainly focused on the eyes, but includes potential one-and-done treatments for Fabry disease and cystic fibrosis. Click to view original post